First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study

CONCLUSION: Nivolumab plus low-dose ipilimumab demonstrated robust and durable clinical benefit and was well tolerated as a first-line treatment for MSI-H/dMMR mCRC. Based on these promising data, randomized studies are warranted.PMID:34637336 | DOI:10.1200/JCO.21.01015

Source: Clinical Colorectal Cancer - October 12, 2021 Category: Cancer & Oncology Authors: Heinz-Josef Lenz Eric Van Cutsem Maria Luisa Limon Ka Yeung Mark Wong Alain Hendlisz Massimo Aglietta Pilar Garc ía-Alfonso Bart Neyns Gabriele Luppi Dana B Cardin Tomislav Dragovich Usman Shah Sandzhar Abdullaev Joseph Gricar Jean-Marie Ledeine Michael Source Type: research